TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors with deep expertise in ophthalmology. Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects, affecting virtually everyone over the age of 40. The company also unveiled its distinguished Scientific Advisory Board, which is composed of globally recognized leaders in vision science, clinical ophthalmology and optical engineering.

“The capital infusion enables us to advance our clinical development and validates our proprietary multifocal lens technology,” said Vartan Ghazarossian, Ph.D., Co-Founder and CEO of TearOptix. “With the strategic guidance of our Scientific Advisory Board, we are moving rapidly to ensure that our products meet the highest standards of safety and clinical performance, establishing a basis for regulatory clearance.”

More than two billion people worldwide are affected by presbyopia, a number expected to grow significantly with global aging. TearOptix’s tear and blink-driven multifocal technology represents a paradigm shift from conventional lenses, delivering unmatched clarity, comfort and seamless vision across all distances.

"Presbyopia remains a major challenge in contact lens-based vision correction,” said Vance Thompson, MD, renowned refractive and cataract surgeon, founder of Vance Thompson Vision, and Co-Founder of TearOptix . “What excites me about TearOptix's novel approach is its potential to transform everyday vision for millions of people. Our breakthrough technology, our exceptional team and advisors, and the strategic funding together form a strong foundation for delivering our transformative solution to patients worldwide.”

TearOptix’s Scientific Advisory Board unites world-class vision experts in academic research, clinical practice, and optical innovation to steer the company’s product development, clinical programs, and commercialization strategy.

Members of the TearOptix Scientific Advisory Board include:

• Dr. Ian Cox – President and Founder, IGC Consulting Group; Adjunct Professor, University of Rochester
• Dr. Jennifer Fogt – Assistant Professor of Optometry, The Ohio State University
• Dr. Damien Gatinel – Head, Anterior and Refractive Surgery Department, Rothschild Foundation, Paris
• Dr. Richard Lindstrom – Founder, Minnesota Eye Consultants; Adjunct Clinical Professor Emeritus, University of Minnesota
• Dr. James Wolffsohn – Professor of Optometry, Aston University, United Kingdom
• Dr. Aaron Zimmerman – Clinical Professor, College of Optometry, The Ohio State University.

“This investment represents a major step forward in our mission to redefine vision correction for presbyopia,” added Dr. Ghazarossian. “It underscores the confidence our investors have in the science behind our technology and the strength of our team. With continued collaboration from our Scientific Advisory Board, we’re accelerating progress toward delivering innovative optical solutions that improve patients’ quality of life.”

About TearOptix

TearOptix, Inc. is redefining presbyopia correction with its proprietary tear- and blink-responsive contact lens technology, delivering exceptional clarity, comfort, and natural vision at all distances. Headquartered in Silicon Valley, the company merges breakthrough optical engineering with world-class clinical expertise to set a new standard in vision care. TearOptix is committed to transforming the lives of millions affected by age-related vision changes through innovation that bridges science and human experience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117349536/en/